Bio-Thera Solutions (688177.CH) - What's Next for Bio-Thera After R&D Setbacks and Years of Losses?
The article analyzed the concerns after theĀ suspension of R&D of its three core products, theĀ challenges of its listed product Qletli,and also the...
403 Views
Genor Biopharma (6998.HK) - Here Is Why the Stock Price Decreased by About 50%
This article analyzed the concerns of Genor Biopharma in terms of core products, competitive landscape, industry characteristics and the potential...
422 Views
ECM Weekly (21 February 2021) - Tencent Lock-Up Expiry, SciClone Pharma, Joinn Lab, Bairong, Betta
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
766 Views
Betta Pharma (č“č¾¾å»čÆ) A+H: Tier 2 Player Struggled to Break Out
The company has a comprehensive range of small molecule product candidates covering lung cancer but is short of the truly innovative drugs.
499 Views
Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma
This article mainly analyzed Innovent in terms of its current listed products (Sintilimab, Bevacizumab, Adalimumab and Rituximab), its pipeline,...
541 Views